Orwin John A 4

What Happened On April 20, 2026, AnaptysBio director John A. Orwin reported a series of derivative transactions that reflect an adjustment of outstanding options related to a separation/spin-off. The filing shows matched dispositions to the issuer and simultaneous grants/acquisitions of options (all at $0) in amounts of 3,311; 10,600; 16,510; 16,510; and 8,250 — an aggregate of 55,181 option-equivalent shares. These were non-cash adjustments (price $0) tied to the company’s Separation and Distribution Agreement and do not represent open-market purchases or sales.

Key Details

• Transaction date: April 20, 2026. Form 4 filed April 22, 2026 (appears timely).
• Transaction types: Multiple dispositions to issuer (D) and grants/acquisitions (A) of derivative interests; all at $0 (non-cash).
• Aggregate adjusted options reported: 55,181 option-equivalent shares (sum of all A entries).
• Shares/ownership after transaction: Not specified in the Form 4 provided.
• Notable footnotes:
  • F1: Adjustments were made pro rata under the Separation and Distribution Agreement; each option was split/adjusted into options to acquire shares of both First Tracks and AnaptysBio.
  • F2: One option reported is fully vested and exercisable.
  • F3: Another option vests 1/12 monthly beginning Feb 6, 2026, subject to continued service.
• No cash proceeds or open-market trades were reported — this is an administrative/options adjustment, not a sale or purchase.

Context This filing documents a derivative adjustment tied to a corporate separation (spin-off) that altered option allocations between AnaptysBio and the new/related company (First Tracks). For retail investors: these kinds of filings often reflect contractual adjustments rather than insider sentiment. Because no shares were sold on the open market and no cash changed hands, this is not a direct buy/sell signal; it notifies investors of a change in the insider’s option holdings and vesting status.